Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, … Read more
Mineralys Therapeutics, Inc. Common Stock (MLYS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.050x
Based on the latest financial reports, Mineralys Therapeutics, Inc. Common Stock (MLYS) has a cash flow conversion efficiency ratio of -0.050x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.87 Million) by net assets ($576.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mineralys Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Mineralys Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Mineralys Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mineralys Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Central Retail Corporation Public Company Limited
BK:CRC
|
0.105x |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
-0.055x |
|
Russel Metals Inc
PINK:RUSMF
|
0.066x |
|
TriCo Bancshares
NASDAQ:TCBK
|
0.034x |
|
Deliveroo Holdings PLC
PINK:DROOF
|
0.203x |
|
Visual China Group Co Ltd
SHE:000681
|
0.012x |
|
Innovative Industrial Properties Inc
NYSE:IIPR
|
0.024x |
|
Ube Industries Ltd
PINK:UBEOF
|
0.002x |
Annual Cash Flow Conversion Efficiency for Mineralys Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual cash flow conversion efficiency of Mineralys Therapeutics, Inc. Common Stock from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $191.26 Million | $-166.31 Million | -0.870x | -158.34% |
| 2023-12-31 | $241.15 Million | $-81.17 Million | -0.337x | -160.21% |
| 2022-12-31 | $-52.27 Million | $-29.22 Million | 0.559x | -11.97% |
| 2021-12-31 | $-22.93 Million | $-14.56 Million | 0.635x | -7.25% |
| 2020-12-31 | $-3.60 Million | $-2.46 Million | 0.685x | -- |